CERo Therapeutics
Business Services · California, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
201 Haskins Way Ste 230, South San Franc...Phone Number
(215) 731-9450Website
cero.bioRevenue
-Stock Symbol
CEROIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About CERo Therapeutics
CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies. The company was incorporated in 2021 and is based in South San Francisco, California.Explore more
CERo Therapeutics Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is CERo Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at CERo Therapeutics
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if CERo Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Check out if CERo Therapeutics is spiking on competitors!
Product Launch: Get notified when CERo Therapeutics launches new products
Click to see if CERo Therapeutics had a recent Job posting/layoffs
Earning: See what the market has to say on CERo Therapeutics recently announced quarterly report
CERo Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once CERo Therapeutics has new funding data
Recommended Actions
Find VP level buyers at CERo Therapeutics
Find 3 more new buyers
Compare Similar Companies to CERo Therapeutics
Compare insights from companies similar to CERo Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
CERo Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
CERo Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about CERo Therapeutics.
CERo Therapeutics financials insights
Gather financial insights about CERo Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Series A
$40M
2025
Other Financing Round
$8M
CERo Therapeutics Tech Stack
A closer look at the technologies used by CERo Therapeutics
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
CERo Therapeutics has administered four doses of CER-1236 and two rounds of lymphodepletion to patient two over a treatment course, with no dose-limiting toxicities (DLTs) reported and no adverse events related to CER-1236.
Medical Research, Pharmaceuticals
Project
CERo Therapeutics has engaged in exploratory discussions with potential pharmaceutical partners at the American Society of Hematology (ASH) meetings, where the company presented the first data from a trial targeting TIM-4 ligand with phagocytic T cells.
Business Development
Project
CERo Therapeutics has amended the CERTINTY-1 protocol in December to add cohorts focused on bone marrow diseases including myelodysplastic syndrome (MDS) and myelofibrosis.
Product Development, Medical Research, Pharmaceuticals
Project
Business Intelligence, Analytics & Insights, Medical Research, Pharmaceuticals
CERo Therapeutics News & Media
CERo Therapeutics Completes Second Ascending Dose Cohort of Phase 1 CER-1236 Trial
Company to initiate third planned cohort at higher dose level, including patients with myelodysplastic syndrome and myelofibrosisCERo Therapeutics Doses Third Patient in Cohort 2 of Phase 1 CER-1236 Trial
Study will advance into expanded patient populations with myelodysplastic syndrome (MDS) and myelofibrosis (MF)CERo Therapeutics Doses Second Patient in Cohort 2 of Phase 1 CER-1236 Trial
Trial advancing with ongoing safety and pharmacologic evaluation and planned expansion into MDS and MFCERo Therapeutics Provides Shareholder Update
Ongoing activities, including new engagement to relist on Nasdaq, new board member, continued advancement of Phase 1 trial into MDS patients, strategic engagement, and continued support from lead investor, underscore the Company’s operational momentum
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding CERo Therapeutics
Sign Up For FreeTo access detailed company insights
CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies. The company was incorporated in 2021 and is based in South S... Read More
